Application of reagent for detecting expression level of MLH1 to preparation of kit for detecting sensitivity of tumor targeted drug

Abstract

The invention discloses a kit for detecting sensitivity of a tumor targeted drug. The kit comprises an optional reagent for detecting the expression level of MLH1. The invention also discloses application of the reagent to detection of the expression level of the MLH1 in preparation of the kit for detecting the sensitivity of the tumor targeted drug. The kit has the advantages that by detecting the expression level of the MLH1, the sensitivity of a tumor patient to the targeted drugs (sorafenib and sunitinib) can be judged, the drug treatment effect on the tumor patient can be predicted in theclinical application, the basis is provided for the patient to take the related treatment measure or decision, and the clinical application prospect is good.

Description

technical field [0001] The invention belongs to the field of tumor molecular biology, and in particular relates to the use of a reagent for detecting the expression level of MLH1 in the preparation of a tumor targeting drug sensitivity detection kit. Background technique [0002] With the development of molecular biology technology, people have a better understanding of the pathogenesis of tumors, and then began to target cell receptors, key genes and regulatory molecules, which is called "targeted therapy". Therefore, Tumor targeting drugs have also become an important drug for the treatment of tumors. Compared with traditional chemotherapy drugs, tumor-targeted drugs have the advantages of strong specificity, obvious curative effect, and less damage to normal tissues. There are two main types of such drugs, monoclonal antibodies and small molecule compounds. Now there are multi-target therapeutic drugs—sorafenib (launched in 2005, sorafenib, BAY43-9006), sunitinib (launch...

AI Technical Summary

Problems solved by technology

However, there is currently a lack of effective biomarkers to screen out subgroups that may be effective for targeted drugs such as sorafenib and sunitinib

At the same time, there are no effective hematological markers to monitor when such drugs become resistant, so that other therapeutic measures can be used in time to inhibit tumor progression

[0005] Mismatch repair protein 1 (MLH1) is a major gene of the DNA mismatch repair system. Studies have shown that MLH1 is closely related to the occurrence of tumors. The decrease or loss of its expression will cause the decrease of the mismatch repair function, so that the spontaneous mutation The rate of increase increases the instability of the genome, leading to abnormal proliferation of cells and cancer

However, there is no report on the relationship between MLH1 expression and the tumor-targeted drug Sorafenib or Sunitinib in the treatment of liver cancer and kidney cancer.

Images